Page 34 - Read Online

Cheng et al. Cancer Drug Resist. 2025;8:46 Page 27 of 28

143. Sun K, Yu J, Hu J, et al. Salicylic acid-based hypoxia-responsive chemodynamic nanomedicines boost antitumor immunotherapy by
modulating immunosuppressive tumor microenvironment. Acta Biomater. 2022;148:230-43. DOI PubMed
144. Gong J, Cheng D, Liu C, et al. Hybrid cell membrane-coated nanoparticles for synergizing sonodynamic therapy and immunotherapy
against triple-negative breast cancer. Adv Healthc Mater. 2025;14:e2404184. DOI PubMed
145. Wang Y, Yu J, Luo Z, et al. Engineering endogenous tumor-associated macrophage-targeted biomimetic nano-RBC to reprogram tumor
immunosuppressive microenvironment for enhanced chemo-immunotherapy. Adv Mater. 2021;33:e2103497. DOI PubMed
146. Cao Y, Qiao B, Chen Q, et al. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for
cancer immunotherapy. Acta Biomater. 2023;160:239-51. DOI PubMed
147. Liu Y, Qiu N, Shen L, et al. Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer. J Control Release.
2020;323:431-41. DOI PubMed PMC
148. Jiang T, Wang B, Wang T, Zhang L, Chen X, Zhao X. TAM-hijacked immunoreaction rescued by hypoxia-pathway-intervened strategy
for enhanced metastatic cancer immunotherapy. Small. 2024;20:e2305728. DOI PubMed
149. Zhao Q, He X, Qin X, et al. Enhanced therapeutic efficacy of combining losartan and chemo-immunotherapy for triple negative breast
cancer. Front Immunol. 2022;13:938439. DOI PubMed PMC
150. Zhang D, Li Q, Chen X, et al. An injectable hydrogel to modulate T cells for cancer immunotherapy. Small. 2022;18:e2202663. DOI
PubMed
151. Wang D, Zhang L, Yang WH, et al. Arginine-loaded nano-calcium-phosphate-stabilized lipiodol pickering emulsions potentiates
transarterial embolization-immunotherapy. Adv Sci. 2025;12:e2410484. DOI PubMed PMC
152. Chen N, Li Z, Liu H, et al. Enhancing PD-1 blockade in NSCLC: reprogramming tumor immune microenvironment with albumin-bound
statins targeting lipid rafts and mitochondrial respiration. Bioact Mater. 2025;49:140-53. DOI PubMed PMC
153. Zhou Z, Liu Y, Song W, et al. Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy.
J Control Release. 2022;352:793-812. DOI PubMed
154. Zhao Z, Dong S, Liu Y, et al. Tumor microenvironment-activable manganese-boosted catalytic immunotherapy combined with PD-1
checkpoint blockade. ACS Nano. 2022;16:20400-18. DOI PubMed
155. Xiong W, Qi L, Jiang N, et al. Metformin liposome-mediated PD-L1 downregulation for amplifying the photodynamic immunotherapy
efficacy. ACS Appl Mater Interfaces. 2021;13:8026-41. DOI PubMed
156. An J, Guo R, Liu M, Hu H, Zhang H. Multi-modal Ca nanogenerator via reversing T cell exhaustion for enhanced
2+
chemo-immunotherapy. J Control Release. 2024;372:715-27. DOI PubMed
157. Yi L, Jiang X, Zhou Z, et al. A hybrid nanoadjuvant simultaneously depresses PD-L1/TGF-β1 and activates cGAS-STING pathway to
overcome radio-immunotherapy resistance. Adv Mater. 2024;36:e2304328. DOI PubMed
158. Wang T, Chen S, Sun J, Li K. Functional co-delivery nanoliposomes based on improving hypoxia for increasing photoimmunotherapy
efficacy of cold tumors. Int J Pharm. 2024;663:124581. DOI PubMed
159. Wang S, Zhou Z, Hu R, et al. Metabolic intervention liposome boosted lung cancer radio-immunotherapy via hypoxia amelioration and
PD-L1 restraint. Adv Sci. 2023;10:e2207608. DOI PubMed PMC
160. Jiang X, Yi L, Li C, et al. Mitochondrial disruption nanosystem simultaneously depressed programmed death ligand-1 and transforming
growth factor-β to overcome photodynamic immunotherapy resistance. ACS Nano. 2024;18:3331-48. DOI PubMed
161. Chen Y, Zuo M, Jana D, et al. Priming of cancer-immunity cycle by alleviating hypoxia-induced ferroptosis resistance and
immunosuppression. Biomaterials. 2025;315:122911. DOI PubMed
162. Wu Q, Liu M, Zhang H, et al. WO 3-x @ferrocene-folic acid composites induce cancer cell death and activate immunity via PTT/CDT.
Small. 2025;21:e2500104. DOI PubMed
163. Zhang X, He C, He X, et al. HIF-1 inhibitor-based one-stone-two-birds strategy for enhanced cancer chemodynamic-immunotherapy. J
Control Release. 2023;356:649-62. DOI PubMed
164. Wang Z, Zhu M, Dong R, et al. TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade
efficacy in gastric cancer. J Nanobiotechnology. 2023;21:440. DOI PubMed PMC
165. Ji Y, Qu S, Shi G, et al. Triggered cascade-activation nanoplatform to alleviate hypoxia for effective tumor immunotherapy guided by
NIR-II imaging. ACS Nano. 2024;18:31421-34. DOI PubMed
166. Taleb M, Atabakhshi-Kashi M, Wang Y, et al. Bifunctional therapeutic peptide assembled nanoparticles exerting improved activities of
tumor vessel normalization and immune checkpoint inhibition. Adv Healthc Mater. 2021;10:e2100051. DOI PubMed
167. Lan J, Zeng R, Li Z, et al. Biomimetic nanomodulators with synergism of photothermal therapy and vessel normalization for boosting
potent anticancer immunity. Adv Mater. 2024;36:e2408511. DOI PubMed
168. Li J, Wei R, Yao W, et al. iRGD-mediated liposomal nanoplatforms for improving hepatocellular carcinoma targeted combination
immunotherapy and monitoring tumor response via IVIM-MRI. J Mater Chem B. 2024;12:9963-78. DOI PubMed
27